Skip to Content

PerkinElmer Inc PKI Stock Quote

| Rating as of

NYSE:PKI

Morningstar‘s Stock Analysis PKI

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

PerkinElmer Delivers Decent Third-Quarter Results; Maintaining Our Fair Value Estimate

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Narrow-moat PerkinElmer reported slightly better-than-expected third-quarter results in its non-COVID-19 operations, which allowed management to maintain its full-year outlook. The company was also able to maintain decent margins despite macroeconomic headwinds as it leveraged volume and pricing increases while also controlling costs. PerkinElmer remains on track to successfully execute the planned divestiture of its analytical, food, and enterprise service business to New Mountain Capital by the first quarter of 2023. We are maintaining our $162 fair value estimate and believe the shares are moderately undervalued.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics PKI

Company Profile PKI

Business Description

PerkinElmer provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments: diagnostics, which includes immunodiagnostics, reproductive health, and applied genomics, and discovery and analytical solutions, composed of life science, industrial, environmental, and food applications. PerkinElmer offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.

Contact
940 Winter Street
Waltham, MA, 02451
T +1 781 663-6900
Industry Diagnostics & Research
Most Recent Earnings Sep 30, 2022
Fiscal Year End Jan 2, 2023
Employees 16,700